小核仁RNA C/D盒88C在非小细胞肺癌患者中的表达  

Expression of small nuclear kernel RNA C/D box 88C in non-small cell lung cancer patients

作　　者：石珍亮[1] 夏文超 沈一梦 刘鑫 Shi Zhenliang;Xia Wenchao;Shen Yimeng;Liu Xin(Department of Thoracic Surgery,Tianjin Chest Hospital,Tianjin 300350,China)

机构地区：[1]天津市胸科医院胸外科,天津300222

出　　处：《中华实验外科杂志》2025年第1期126-129,共4页Chinese Journal of Experimental Surgery

基　　金：吴阶平医学基金会临床科研专项资助基金项目(320.6750.2021-17-4)。

摘　　要：目的探讨小核仁RNA C/D盒88C(SNORD88C)在非小细胞肺癌(NSCLC)患者中的表达及对NSCLC的诊断效能。方法选取2020年7月至2022年6月天津市胸科医院收治的96例NSCLC患者为观察组,检测血清SNORD88C、硬脂酰辅酶A去饱和酶1(SCD1)、细胞周期蛋白E(Cyclin E)和微管相关蛋白Ⅰ轻链3B(LC3B)的表达水平;分析SNORD88C表达水平与NSCLC患者临床病理特征的关系;Logistic回归分析影响NSCLC的危险因素;受试者工作特征(ROC)曲线评估SNORD88C对NSCLC的诊断效能。组间差异采用配对t检验或卡方检验进行统计分析。结果观察组SNORD88C、SCD1和Cyclin E表达水平(1.10±0.20、15.82±5.06、33.16±6.47)显著高于对照组(0.82±0.17、12.96±3.68、20.48±8.65),差异有统计学意义(t=10.090、4.372、11.050,P<0.01)。观察组LC3B表达水平(9.73±2.99)显著低于对照组(12.80±3.04),差异有统计学意义(t=6.939,P<0.01)。TNM分期为Ⅲ~Ⅳ患者SNORD88C表达水平(1.15±0.21)高于TNM分期为Ⅰ~Ⅱ患者(0.99±0.16),差异有统计学意义(t=3.570,P<0.01)。发生淋巴转移患者SNORD88C表达水平(1.12±0.18)高于未发生淋巴转移患者(0.94±0.12),差异有统计学意义(t=4.435,P<0.01)。血清SNORD88C截断值为0.830对预测NSCLC具有良好的灵敏度(93.75%)和特异性(60.00%),曲线下面积(AUC)为0.855[95%置信区间(CI):0.803~0.908,P<0.05]。结论血清SNORD88C水平在NSCLC患者中显著升高,是NSCLC患病的危险因素。Objective To investigate the expression of small nucleolar RNA C/D box 88C(SNORD88C)in patients with non-small cell lung cancer(NSCLC)and the diagnostic efficacy of NSCLC.Methods Totally,96 NSCLC patients admitted to Tianjin Chest Hospital from July 2020 to June 2022 were selected as the observation group,and the expression levels of serum SNORD88C,stearoyl-coa desaturase 1(SCD1),Cyclin E and microtubule-associated proteinⅠlight chain 3B(LC3B)were detected.The relationship between SNORD88C expression level and clinicopathological characteristics of NSCLC patients was analyzed.Logistic regression was used to analyze the risk factors of NSCLC.The receiver operating characteristic(ROC)curve was used to evaluate the diagnostic efficacy of SNORD88C for NSCLC.Differences between groups were statistically analyzed using paired t test or chi-square test.Results The expression levels of SNORD88C,SCD1 and Cyclin E in the observation group(1.10±0.20,15.82±5.06,33.16±6.47)were significantly higher than those in the control group(0.82±0.17,12.96±3.68,20.48±8.65,respectively)(t=10.090,4.372,11.050,P<0.01).The expression level of LC3B in the observation group(9.73±2.99)was significantly lower than that in the control group(12.80±3.04)(t=6.939,P<0.01).The expression level of SNORD88C in patients with TNM stageⅢ-Ⅳ(1.15±0.21)was significantly higher than that in patients with TNM stageⅠ-Ⅱ(0.99±0.16)(t=3.570,P<0.01).The expression level of SNORD88C in patients with lymph node metastasis(1.12±0.18)was significantly higher than that in patients without lymph node metastasis(0.94±0.12)(t=4.435,P<0.01).The cut-off value of serum SNORD88C was 0.830,which had a good sensitivity(93.75%)and specificity(60.00%)for predicting NSCLC,and the area under the curve(AUC)was 0.855[95%confidence interval(CI):0.803-0.908,P<0.05].Conclusion Serum SNORD88C level is significantly increased in patients with NSCLC,which is a risk factor for NSCLC and has good diagnostic efficacy.

关 键 词：非小细胞肺癌 自噬 增殖 

分 类 号：R734.2[医药卫生—肿瘤]